在 COVID 疫苗接种时代，用 PET/CT 对乳腺癌进行分期的挑战。
The Challenge of Staging Breast Cancer With PET/CT in the Era of COVID Vaccination.
机构信息
From the Breast Unit.
Department of Nuclear Medicine, Royal Free Hospital.
出版信息
Clin Nucl Med. 2021 Dec 1;46(12):1006-1010. doi: 10.1097/RLU.0000000000003683.
We report a case series of biopsy-proven reactive axillary lymph nodes, which were avid on FDG PET/CT in breast cancer patients post COVID-19 vaccination. With 4 cases presenting in a consecutive 10-day period, it became apparent that metabolically active axillary lymphadenopathy is an adverse effect of COVID-19 vaccines, currently being deployed worldwide. This may lead to patients undergoing unnecessary biopsy. We have started taking a COVID-19 vaccine status history before PET/CT. If enlarged/metabolically active axillary nodes are identified in the ipsilateral vaccinated arm, then axillary ultrasound at 4 weeks is suggested.
我们报告了一系列活检证实的反应性腋窝淋巴结病例，这些病例在 COVID-19 疫苗接种后的乳腺癌患者的 FDG PET/CT 上呈阳性。由于在连续的 10 天内出现了 4 例病例，因此很明显，代谢活跃的腋窝淋巴结病是目前在全球范围内部署的 COVID-19 疫苗的一种不良反应。这可能导致患者接受不必要的活检。我们已经开始在 PET/CT 前询问 COVID-19 疫苗接种史。如果在同侧接种疫苗的手臂中发现腋窝淋巴结肿大/代谢活跃，则建议在 4 周时进行腋窝超声检查。
Zotero 插件